232 related articles for article (PubMed ID: 16630997)
1. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
Cleland JG; Charlesworth A; Lubsen J; Swedberg K; Remme WJ; Erhardt L; Di Lenarda A; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson PA;
J Am Coll Cardiol; 2006 Apr; 47(8):1603-11. PubMed ID: 16630997
[TBL] [Abstract][Full Text] [Related]
2. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
[TBL] [Abstract][Full Text] [Related]
3. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
4. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C
Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173
[TBL] [Abstract][Full Text] [Related]
5. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Remme WJ; Torp-Pedersen C; Cleland JG; Poole-Wilson PA; Metra M; Komajda M; Swedberg K; Di Lenarda A; Spark P; Scherhag A; Moullet C; Lukas MA
J Am Coll Cardiol; 2007 Mar; 49(9):963-71. PubMed ID: 17336720
[TBL] [Abstract][Full Text] [Related]
7. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Delea TE; Stanford R; Hagiwara M; Edelsberg JS; Oster G
Int J Cardiol; 2005 Mar; 99(1):117-24. PubMed ID: 15721509
[TBL] [Abstract][Full Text] [Related]
8. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
Poole-Wilson PA
Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
[TBL] [Abstract][Full Text] [Related]
9. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
Torp-Pedersen CT;
Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
[No Abstract] [Full Text] [Related]
10. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Swedberg K; Olsson LG; Charlesworth A; Cleland J; Hanrath P; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson P
Eur Heart J; 2005 Jul; 26(13):1303-8. PubMed ID: 15767288
[TBL] [Abstract][Full Text] [Related]
11. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
Boman K; Jansson JH; Nilsson T; Swedberg K; Cleland JG; Poole-Wilson P
Thromb Res; 2010 Feb; 125(2):e46-50. PubMed ID: 19762071
[TBL] [Abstract][Full Text] [Related]
12. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M;
J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808
[TBL] [Abstract][Full Text] [Related]
13. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Remme WJ; Cleland JG; Erhardt L; Spark P; Torp-Pedersen C; Metra M; Komajda M; Moullet C; Lukas MA; Poole-Wilson P; Di Lenarda A; Swedberg K
Eur J Heart Fail; 2007 Nov; 9(11):1128-35. PubMed ID: 17716943
[TBL] [Abstract][Full Text] [Related]
14. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Torp-Pedersen C; Metra M; Charlesworth A; Spark P; Lukas MA; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Remme WJ; Scherhag A;
Heart; 2007 Aug; 93(8):968-73. PubMed ID: 17237130
[TBL] [Abstract][Full Text] [Related]
15. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
Fowler MB
Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
Levy AR; Briggs AH; Demers C; O'Brien BJ
Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
[TBL] [Abstract][Full Text] [Related]
18. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
[TBL] [Abstract][Full Text] [Related]
19. Effect of carvedilol on survival in severe chronic heart failure.
Packer M; Coats AJ; Fowler MB; Katus HA; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Roecker EB; Schultz MK; DeMets DL;
N Engl J Med; 2001 May; 344(22):1651-8. PubMed ID: 11386263
[TBL] [Abstract][Full Text] [Related]
20. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
Cleland JG; Goode K; Erhardt L; Remme WJ; Charlesworth A; Poole-Wilson PA; Di Lenarda A; Hanrath P; Komajda M; Metra M; Swedberg K; Torp-Pedersen C;
Cardiovasc Drugs Ther; 2004 Mar; 18(2):139-52. PubMed ID: 15162076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]